Working… Menu

Efficacy and Safety Study of Panobinostat in Patients With Metastatic Hormone Refractory Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00667862
Recruitment Status : Completed
First Posted : April 28, 2008
Last Update Posted : November 16, 2016
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:
This Phase II single dose study is designed to characterize the safety, tolerability and efficacy of i.v. panobinostat as a single-agent treatment in patients with hormone refractory prostate cancer.

Condition or disease Intervention/treatment Phase
Prostate Cancer Drug: Panobinostat Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 35 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A Phase II, Open Label, Single Arm Study of i.v. Panobinostat (LBH589) in Patients With Metastatic Hormone Refractory Prostate Cancer
Study Start Date : April 2008
Actual Primary Completion Date : November 2010
Actual Study Completion Date : November 2010

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Panobinostat Drug: Panobinostat

Primary Outcome Measures :
  1. Determine progression-free survival at 24 weeks [ Time Frame: 24 weeks ]

Secondary Outcome Measures :
  1. Assess the safety and tolerability of LBH589 [ Time Frame: at LPLV for each patient ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Confirmed diagnosis of adenocarcinoma of the prostate
  • Patients with metastatic hormone refractory prostate cancer
  • Patients that have had at least one, but not more than two prior cytotoxic treatments for prostate cancer
  • Evidence of disease progression by at least one of the following

    1. two or more lesions on bone scan
    2. progressive measurable disease
    3. two documented increases in PSA
  • Willing to use contraception throughout the study and for 12 weeks after study completion

Exclusion criteria:

  • History or clinical signs of CNS disease
  • History of other cancers not curatively treated with no evidence of disease for more than 5 years
  • Prior radiotherapy within 3 weeks of starting study treatment
  • Prior radiopharmaceuticals (strontium, samarium)
  • Impaired cardiac function
  • Heart disease
  • Liver or renal disease with impaired function

Other protocol-defined inclusion/exclusion criteria may apply

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00667862

Layout table for location information
United States, Maryland
University of Maryland
Baltimore, Maryland, United States, 21201
Johns Hopkins Hospital
Baltimore, Maryland, United States, 21287
United States, Missouri
Washington University
St. Louis, Missouri, United States, 63130
United States, New York
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
United States, Wisconsin
University of Wisconsin
Madison, Wisconsin, United States, 53706-1481
Sponsors and Collaborators
Novartis Pharmaceuticals
Layout table for investigator information
Study Director: Novartis Pharmaceuticals Novartis Pharmeceuticals

Additional Information:
Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals Identifier: NCT00667862     History of Changes
Other Study ID Numbers: CLBH589C2208
First Posted: April 28, 2008    Key Record Dates
Last Update Posted: November 16, 2016
Last Verified: November 2016
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Prostate-Specific Antigen
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents
Histone Deacetylase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action